ARS Pharmaceuticals, Inc.
NASDAQ:SPRY · NASDAQ Global Market
-$0.35 today
Vol 2.27M · Avg 1.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.9%
avg 27.5%
ROIC
-62.2%
avg -56.6%
ROA
-52.3%
avg -42.5%
Analysis
ROA is currently the strongest return metric at -52.3% versus its period average of -42.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard Lowenthal MSMSEL | Co-Founder, CEO & Director | $3.48M | — | 60 | $875,000.00 | 0.88% |
Sarina Tanimoto | Co-Founder & Chief Medical Officer | $3.18M | — | 57 | $875,000.00 | 0.88% |
Brian T. Dorsey | Chief Operations Officer | $706,970.00 | — | 57 | $240,000.00 | 0.24% |
Justin Chakma | Chief Business Officer | $682,700.00 | — | 36 | $240,000.00 | 0.24% |
Alexander A. Fitzpatrick | Chief Legal Officer & Secretary | $677,145.00 | — | 59 | $90,910.00 | 0.09% |
Eric Karas | Chief Commercial Officer | $618,614.00 | — | 53 | $37,176.00 | 0.04% |
Donn Casale | President | — | — | 53 | $0.00 | <0.01% |
Daniel Relovsky | Senior Vice President of Marketing | — | — | — | — | — |
Kathleen D. Scott | Chief Financial Officer | — | — | — | $240,000.00 | 0.24% |
Lynda Harris | Vice President of Human Resources | — | — | — | — | — |
Robert Bell | Co-Founder & Chief Science Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$10.65M
Net Sentiment
$10.65M
Net selling
Most Active
Karas Eric
2 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $10.65M over the last 12 months. That adds up to net selling of $10.65M. Karas Eric was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +116.6% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +116.6% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.68B
GH Research PLC
NASDAQ:GHRS
$1.48B
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$1.31B
Savara Inc.
NASDAQ:SVRA
$1.11B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$884.49M
Kura Oncology, Inc.
NASDAQ:KURA
$854.01M
Rezolute, Inc.
NASDAQ:RZLT
$489.16M
ProKidney Corp.
NASDAQ:PROK
$261.47M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$184.68M
Who manages SPRY?
ARS Pharmaceuticals, Inc. (SPRY) lists 11 active executives. The top listed executive is Justin Chakma, Chief Business Officer.
Are SPRY insiders buying or selling?
Recent insider activity shows net buying of $18.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.